In December 2008, C.B. Fleet Co. recalled Fleet Phospho-Soda after the FDA announced that when taken at high doses, oral sodium phosphate products increase the risk of kidney injury. Oral sodium phosphate products like Fleet Phospho-Soda are sold as laxatives. However, for a number of years, Fleet has marketed the use of Fleet Phospho-Soda at double doses as a bowel cleanser for colonoscopy preparation. Lawsuits are pending against C.B. Fleet, alleging that the plaintiffs suffered acute phosphate nephropathy after taking double doses of Fleet Phospho-Soda. According to C.B. Fleet, there are at least 38 federal lawsuits pending in 13 different states. Recently, the company filed a motion seeking to have all of the federal lawsuits consolidated in one court as part of a multidistrict litigation or MDL. C.B. Fleet argues that such centralization will be more convenient for the parties and witnesses, and will promote efficiency.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.